Releaf in the Press: Highlights from the Medical Cannabis Sector 2024
2 min read
Lucy MacKinnon
Contents
Releaf has been at the forefront of the UK medical cannabis sector throughout 2024, garnering widespread media attention for its innovative patient-first approach and groundbreaking initiatives. From leading the conversation around accessibility to driving awareness of medical cannabis treatment options, Releaf has consistently made headlines, shaping the narrative of this rapidly evolving industry. With notable features in national publications and influential platforms, the spotlight on Releaf reflects its commitment to transforming lives and redefining the future of medical cannabis care in the UK.
The Times: June 2024
"Legal cannabis by post: inside the farm behind a British first"
Yahoo! News: November 2024
"Mum praises ‘miracle’ cannabis vape for ‘saving my son’ after mainstream treatments failed"
The Business Desk: October 2024
"Historic medical cannabis deal set to create jobs for Nottingham firm"
Manchester Evening News: November 2024
"Man fit the criteria for a 'cannabis card' after a quick Google"
MSN News: November 2024
"I'm a social worker and I use cannabis daily for health reasons' says 47-year-old Milton Keynes woman"
The Mirror: October 2024
"My son was wasting away, cannabis came to his rescue when doctors couldn’t"
The Daily Start: December 2024
"Releaf medical cannabis helped me reduce my pain and anxiety"
BBC Radio Cambridgeshire: December 2024
Share article
Did you like this article?
It is important to seek medical advice before starting any new treatments. The patient advisors at Releaf are available to provide expert advice and support. Alternatively, click here to book a consultation with one of our specialist doctors.
Elevate your wellness with medical cannabis
Get comprehensive care, convenience, and confidence with an all-in-one treatment plan.
Am I eligible?Authors
With five years of journalism and healthcare content creation under her belt, Lucy strives to improve medical cannabis awareness and access in the UK by producing high quality, credible content.
Editorial Policy
All of our articles are written by medical cannabis experts, guided by strict sourcing guidelines, and reference peer-reviewed studies and credible academic research. Our expert clinical team and compliance specialists provide valuable insights to ensure accuracy when required. Learn more in our editorial policy.
Need more help?
Blog Categories
Further reading
Peace of mind price tags: Why all our medical cannabis flowers are £7.99 per gram for Releaf+ patients
Many Releaf patients say their medical cannabis treatment has been ‘transformative’ or ‘life-changing’ - but some have also told us at first, they were wary of the cost. Unknown pricing adds uncertainty - and unnecessary stress. But at Releaf, we believe consistency matters. That’s why all prescribed cannabis flowers are priced at £7.99 per gram for those on our subscription plan: Releaf+. Read on to find out more about our consistent costs, how the Releaf+ subscription supports it, and why £7.99 per gram offers more than affordability - it offers confidence.
Lucy MacKinnon
Real Patient Voices: With age comes wisdom - medical cannabis and me
Chronic pain, sleep difficulties, and reduced mobility often increase with age - but often, so does wisdom. In this latest edition of our Real Patient Voices series, we share the experiences of Peter, Mary, and Simon - Releaf patients in their 60s, 70s, and beyond - who turned to cannabis-based treatments later in life. From managing trigeminal neuralgia to regaining energy in the garden, their stories highlight how it’s never too late to explore new approaches to wellbeing.
Lucy MacKinnon
How blogs convert: Educational content is key
Releaf’s educational content is carefully planned, clinically informed, and always human written. In a space flooded with noise, we’ve built a resource that patients trust. From first click until they are fully set up (and beyond), our blog helps people feel informed, understood, and ready to take the next step, and the data shows it works.
Sam North